Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) : a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
Objectives: The aims of this study were to update the evidence on the incidence and prevalence rates of vaccine preventable infections (VPI) in patients with autoimmune inflammatory rheumatic diseases (AIIRD) and compare the data to the general population when available.
Methods: A literature search was performed using Medline, Embase and Cochrane library (October 2009 to August 2018). The primary outcome was the incidence or prevalence of VPI in the adult AIIRD population. Meta-analysis was performed when appropriate.
Results: Sixty-three publications out of 3876 identified records met the inclusion criteria: influenza (n=4), pneumococcal disease (n=7), hepatitis B (n=10), herpes zoster (HZ) (n=29), human papillomavirus (HPV) infection (n=13). An increased incidence of influenza and pneumococcal disease was reported in patients with AIIRD. HZ infection-pooled incidence rate ratio (IRR) was 2.9 (95% CI 2.4 to 3.3) in patients with AIIRD versus general population. Among AIIRD, inflammatory myositis conferred the highest incidence rate (IR) of HZ (pooled IRR 5.1, 95% CI 4.3 to 5.9), followed by systemic lupus erythematosus (SLE) (pooled IRR 4.0, 95% CI 2.3 to 5.7) and rheumatoid arthritis (pooled IRR 2.3, 95% CI 2.1 to 2.6). HPV infection-pooled prevalence ratio was 1.6, 95% CI 0.7 to 3.4 versus general population, based on studies mainly conducted in the SLE population in Latin America and Asia. Pooled prevalence of hepatitis B surface antigen and hepatitis B core antibody in patients with AIIRD was similar to the general population, 3%, 95% CI 1% to 5% and 15%, 95% CI 7% to 26%, respectively.
Conclusion: Current evidence shows an increased risk of VPI in patients with AIIRD, emphasising that prevention of infections is essential in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
RMD open - 5(2019), 2 vom: 21., Seite e001041 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Furer, Victoria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune diseases |
|---|
| Anmerkungen: |
Date Completed 27.04.2020 Date Revised 27.04.2020 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2019-001041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302778829 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302778829 | ||
| 003 | DE-627 | ||
| 005 | 20231225111437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2019-001041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1009.xml |
| 035 | |a (DE-627)NLM302778829 | ||
| 035 | |a (NLM)31673420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Furer, Victoria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) |b a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2020 | ||
| 500 | |a Date Revised 27.04.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Objectives: The aims of this study were to update the evidence on the incidence and prevalence rates of vaccine preventable infections (VPI) in patients with autoimmune inflammatory rheumatic diseases (AIIRD) and compare the data to the general population when available | ||
| 520 | |a Methods: A literature search was performed using Medline, Embase and Cochrane library (October 2009 to August 2018). The primary outcome was the incidence or prevalence of VPI in the adult AIIRD population. Meta-analysis was performed when appropriate | ||
| 520 | |a Results: Sixty-three publications out of 3876 identified records met the inclusion criteria: influenza (n=4), pneumococcal disease (n=7), hepatitis B (n=10), herpes zoster (HZ) (n=29), human papillomavirus (HPV) infection (n=13). An increased incidence of influenza and pneumococcal disease was reported in patients with AIIRD. HZ infection-pooled incidence rate ratio (IRR) was 2.9 (95% CI 2.4 to 3.3) in patients with AIIRD versus general population. Among AIIRD, inflammatory myositis conferred the highest incidence rate (IR) of HZ (pooled IRR 5.1, 95% CI 4.3 to 5.9), followed by systemic lupus erythematosus (SLE) (pooled IRR 4.0, 95% CI 2.3 to 5.7) and rheumatoid arthritis (pooled IRR 2.3, 95% CI 2.1 to 2.6). HPV infection-pooled prevalence ratio was 1.6, 95% CI 0.7 to 3.4 versus general population, based on studies mainly conducted in the SLE population in Latin America and Asia. Pooled prevalence of hepatitis B surface antigen and hepatitis B core antibody in patients with AIIRD was similar to the general population, 3%, 95% CI 1% to 5% and 15%, 95% CI 7% to 26%, respectively | ||
| 520 | |a Conclusion: Current evidence shows an increased risk of VPI in patients with AIIRD, emphasising that prevention of infections is essential in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a infections | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Rondaan, Christien |e verfasserin |4 aut | |
| 700 | 1 | |a Heijstek, Marloes |e verfasserin |4 aut | |
| 700 | 1 | |a van Assen, Sander |e verfasserin |4 aut | |
| 700 | 1 | |a Bijl, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Agmon-Levin, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Breedveld, Ferdinand C |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amelio, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Dougados, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Kapetanovic, Meliha Crnkic |e verfasserin |4 aut | |
| 700 | 1 | |a van Laar, Jacob M |e verfasserin |4 aut | |
| 700 | 1 | |a Ladefoged de Thurah, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Landewé, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Molto, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Ladner, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Schreiber, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Smolar, Leo |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Jim |e verfasserin |4 aut | |
| 700 | 1 | |a Warnatz, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Wulffraat, Nico M |e verfasserin |4 aut | |
| 700 | 1 | |a Elkayam, Ori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 5(2019), 2 vom: 21., Seite e001041 |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2019 |g number:2 |g day:21 |g pages:e001041 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2019-001041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2019 |e 2 |b 21 |h e001041 | ||